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The set point of calcium and the reduction of parathyroid hormone in
hemodialysis patients. Since in some studies in hemodialysis patients
calcitriol treatment has resulted in a reduction of both parathyroid
hormone (PTH) levels and the set point of calcium, it has been suggested
that the set point of calcium reflects a reduction in the magnitude of
hyperparathyroidism. However, others have maintained that the set point
of calcium is primarily an indicator of the serum calcium at which PTH is
secreted and may be dissociated from the magnitude of hyperparathyroid-
ism. The present study was designed to evaluate how a reduction in PTH
levels associated with an increase in the predialysis (basal) serum calcium
would affect the set point of calcium. Two different treatments were used
to produce a reduction in PTH that was associated with an increase in
predialysis serum calcium. In the first group, hemodialysis patients re-
ceived 2 rg of intravenous calcitriol and were dialyzed with a 3.5 mEq/liter
calcium dialysate for six weeks; in the second group, hemodialysis patients
were dialyzed with a 4 mEq/liter calcium dialysate and had oral calcium
supplementation increased for six weeks. In both groups, low and high
calcium studies were performed to determine the PTH-calcium relation-
ship before treatment, at the end of six weeks of treatment, and six weeks
after the discontinuation of treatment. In the calcitriol group, the predi-
alysis calcium increased from 9.62 0.34 to 10.56 0.31 mgldl, P < 0.05
and the Set point of calcium increased from 9.34 0.23 to 9.79 0.25
mgldl, P < 0.05 at the same time as maximally stimulated PTH decreased
from 2637 687 to 1555 617 pg/mI, P < 0.05. In the high calcium
dialysate group, the predialysis serum calcium increased from 9.19 0.31
to 9.84 0.28 mg/dl, P < 0.05, and set point of calcium increased from
9.01 0.28 to 9.39 0.22 mg/dl, P < 0.05 at the same time as maximally
stimulated PTH decreased from 1642 450 to 1349 513 pg/mI, P <
0.05. Discontinuation of treatment for six weeks resulted in a return to
pretreatment values. In conclusion, our results would suggest that (1) the
Set point of calcium may not be a reliable indicator of the magnitude of
hyperparathyroidism during calcitriol treatment, and (2) PTH secretion
may adapt to the ambient serum calcium concentration.
In most studies in hemodialysis patients, calcitriol treatment has
resulted in a reduction in parathyroid hormone (PTH) levels
[1—41. However, while ealcitriol treatment of dialysis patients with
secondary hyperparathyroidism has been shown to reduce PTH
levels, the effect of calcitriol on the set point of calcium, defined
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as the serum calcium concentration at which maximal PTH
secretion is reduced by 50% [5], is controversial inasmuch as some
studies have reported a reduction in the set point of calcium [3, 6,
7], while in other studies, the set point of calcium did not change
despite a reduction in PTH levels [2, 4, 8, 9]. Moreover, it has
been suggested that the set point of calcium reflects the reduction
in the magnitude of hyperparathyroidism, and thus an inability to
reduce the set point of calcium indicates a refractoriness to
treatment that may require a parathyroidectomy [3, 7, 91.
The concept that the set point of calcium may be related to the
mass of the parathyroid glands was first suggested as a result of a
series of in vitro studies by Brown et al [10, 11] and a study in
neonatal calves by Keaton et al [12]. As a result of these studies,
the concept was generated that the set point of calcium may be an
indicator of parathyroid gland mass, or in clinical terms, the
magnitude of hyperparathyroidism. However, in vivo, PTH secre-
tion is not only dependent on the serum calcium concentration,
but also the serum calcium concentration is a function of the effect
of PTH on target organs such as kidney and bone. Moreover, a
dissociation between the set point of calcium and the magnitude
of hyperparathyroidism may become particularly apparent in the
setting of renal failure in which skeletal resistance to the calcemic
action of PTH [13], an inability to modulate renal calcium
excretion [14], a calcitriol deficiency [15], and hyperphosphatemia
[13] are generally present.
Previous studies have shown that the serum calcium concentra-
tion is tightly regulated in the normal human [16]. However, the
serum calcium concentration varies considerably among dialysis
patients. In a recent study in hemodialysis patients, we have
observed that the range of serum calcium between maximal and
minimal PTH was constant although the basal serum calcium was
different [17]. In another study in which the PTH response to
hypocalcemia was evaluated in hemodialysis patients with a broad
range of predialysis serum calcium, PTH secretion also appeared
to vary according to the ambient serum calcium [18]. Such findings
resulted in our questioning whether PTH secretion in the dialysis
patient may adapt to the ambient serum calcium.
The goal of the present study was to evaluate in a group of
hemodialysis patients with basal PTH levels > 250 pg/mI, the
effect that intentionally increasing the serum calcium by two
different methods had on the set point of calcium and PTH
secretion. Serum calcium was increased either by treatment with
(I) calcitriol and a high normal dialysate calcium concentration
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(3.5 mEq/liter) or (2) an increased calcium dialysate concentra-
tion (4 mEqlliter) and supplemental oral calcium.
Methods
Eleven maintenance hemodialysis patients were studied. All
patients had predialysis intact PTH levels greater than 250 pg/mI
at the start of the study. Before the start of the study, patients
were dialyzed for 3.5 to four hours thrice weekly with a dialysate
calcium concentration that ranged from 2.5 to 3.5 mEq/liter. Their
mean age at the time of study was 49.4 4.6 years (range 24 to 72
years) and the mean duration of dialysis was 59.8 11.6 months
(range 7 to 136 months). Six patients were male and five were
female. All patients used calcium carbonate as their primary
phosphate binder. None of the patients had received any calcitriol
or other forms of vitamin D for at least six weeks prior to study.
Studies were performed at the hemodialysis units of the Univer-
sit)' of California at Irvine and the West Los Angeles VA Medical
Center. The protocol was approved by the appropriate committee
for human studies at both institutions and all patients gave
informed consent.
As described in our previous studies [2, 4, 17—19], the PTH
response to hypo- and hypercalcemia was evaluated. Briefly, a low
calcium hemodialysis (1 mEq/liter) was performed to induce
hypocalcemia and maximally stimulate PTH and a high calcium
hemodialysis (4 mEq/liter) was performed to induce hypercalce-
mia and maximally inhibit PTH. Blood for PTH and calcium was
obtained at the start of the low calcium dialysis and every 15
minutes until the serum calcium decreased to 7.5 mg/dl or the
dialysis treatment was finished. The following week a high calcium
dialysis was performed and blood for PTH and calcium was
obtained at the start and every 15 to 30 minutes throughout
hemodialysis.
Following the evaluation of the PTH response to hypo- and
hypercalcemia, the purpose was to learn the effect that an increase
in the predialysis serum calcium would have on the PTH-calcium
curve and whether an increase in calcium due to calcitriol would
be different than a calcium increase based on dialysate calcium
and oral calcium supplementation. Accordingly, patients were
randomized to two groups; in Group I (N = 5), patients received
2 jg of intravenous calcitriol after each hemodialysis and were
dialyzed with a 3.5 mEq/liter calcium dialysate; in Group II (N =
6), the patients were dialyzed with a 4 mEq/liter calcium dialysate
and the prescribed amount of oral calcium was increased. Patients
were maintained on their respective protocols for six weeks and
provided that the predialysis serum calcium had increased, the low
and high calcium studies were repeated. Three patients on the
high calcium dialysate protocol and one patient receiving calcitriol
required ten weeks for an increase in the predialysis serum
calcium and were restudied at that time. After the second low and
high calcium studies, calcitriol or the high calcium dialysate was
discontinued, and the dialysate calcium and the prescribed
amount of oral calcium were changed to prestudy levels. Six weeks
later the low and high calcium dialysis studies were repeated.
During each of the three low and high calcium dialysis studies,
blood flow, dialysaie flow, and dialyzer size were the same for the
individual patient.
From the data obtained during dialysis-induced hypo- and
hypercalcemia, the following terms were defined: (1) basal PTH
(PTHbase) was the predialysis PTH level; (2) maximal PTH
(PTHmax) was the highest PTH level observed in response to
hypocalcemia and which an additional reduction of the serum
calcium did not further increase the PTH value; (3) minimal PTH
(PTHmin) was the lowest PTH level during suppression by
hypercalcemia and which a further increase in the serum calcium
did not result in any additional decrease in PTH; (4) the ratio of
basal to maximal PTH (Basal/Max PTH) was the basal PTH
divided by the maximal PTH and this fraction was multiplied by
100 to provide a percentage; in normal volunteers, this ratio is 20
to 25% [20]; (5) the ratio of minimal to maximal PTH (Mm/Max
PTH) was the minimal PTH divided by the maximal PTH and this
fraction was multiplied by 100 to provide a percentage; in normal
volunteers, this ratio is 3 to 5% [201; (6) the set point of calcium
was defined as we have done previously [2, 4, 17, 19] as the serum
calcium concentration at which maximal PTH secretion was
reduced by 50%; (7) the basal serum calcium was the serum
calcium concentration at the basal (predialysis) PTH; (8) the
serum calcium at maximal PTH (Cam) was the serum calcium
concentration at which the PTH level was first observed to be
maximal or within 10% of the maximal PTH; this definition was
used because the PTH-calcium curve is sigmoidal and as the PTH
value approaches the asymptotic portion of the curve, consider-
able variation in serum calcium can be observed during small
changes in PTH; similarly, for the same reason, (9) the serum
calcium at minimal PTH (Camin) was the serum calcium concen-
tration at which the PTH level was first observed to be minimal or
within 10% of the minimal PTH.
Intact PTH was measured with an immunoradiometric assay for
parathyroid hormone (Allegro, Nichols Institute, San Juan Cap-
istrano, CA, USA). Normal values are 10 to 65 pg/ml and the
range of the standard curve is 0 to 1400 pg/mI; when PTH values
were greater than 1400 pg/ml, appropriate dilutions were per-
formed. Serum calcium was measured at bedside during the low
and high calcium studies with an automated calcium analyzer
(Calcette, Precision Systems mc, Natick, MA, USA). At other
times, serum calcium and phosphorus were measured with stan-
dard automated laboratory techniques.
Statistics
For comparisons among the defined parameters obtained dur-
ing the three low and high calcium studies, repeated measures
ANOVA was used followed by the Fisher LSD test for multiple
comparisons. For comparisons between the two randomized
groups, the unpaired Student's t-test was used. A P value less than
0.05 was considered significant. Results are expressed as the mean
SE.
Results
At the start of the study the mean KT/V was 1.31 0.08, and
the mean predialysis hematocrit, albumin, creatinine, and serum
aluminum were 28.3 1.0%, 4.0 0.1 g/dl, 12.8 0.1 mg/dl, and
19.9 4.5 jig/liter, respectively. After randomization, Groups I
and II were similar with respect to age (I, 47 6 vs. II, 51 7
years), sex (1, 3 males and 2 females vs. II, 3 males and 3 females)
and duration of dialysis (I, 65 21 vs. II, 55 13 months). As
shown in Table 1, the predialysis serum calcium, PTH, phospho-
rus, and alkaline phosphatase levels were not different between
the two groups after randomization, after treatment with calcitriol
or a high calcium dialysate, and after discontinuation of these
treatments.
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Table 1. Biochemical data in the two groups at three intervals
PR
I
n=5
E'
II
n=6
POS
I
n=5
Tb
II
n=6
POS
I
n=5
T1'
II
n=6
Serum
PTH 992± 810± 642± 610± 935± 908±
(pg/mI) 257 266 285 265 409 362
Calcium 9.62± 9.19± 10.56± 9.84± 9.94± 9.26±
(mg/dl) 0.34 0.31 0.31 0.28 0.29 0.26
Phosphorus 5.12± 6.17± 6.12± 6.00± 5.96± 5.90±
(mg/dl) 0.61 0.73 0.71 1.10 0.65 0.76
Alkaline 445± 297± 441± 280± 399± 247±
Phosphatase 300 69 357 81 319 70
(lU/L)
Mean SE
PRE—before calcitriol (I) or a high calcium dialysate (II)
h POST—after treatment with calcitriol (I) or a high calcium dialysate
(II)
POST1—after discontinuation of calcitriol (I) or a high calcium
dialysate (II)
Table 2. Biochemical data in the calcitriol group.
PRE POST5 POST1C
PTHmax (pg/mI) 2637 687 1555 617* 2441 896
PTHbase (pg/mI) 992 257 642 285 935 409
PTHmin (pg/mI) 584 214 495 290 428 185
Basal/Max PTH (%) 40 6 36 7 36 10
Mm/Max PTH (%) 21 4 24 5 17 3
Basal Calcium (mg/dl) 9.62 .34 10.56 .31t 9.94 .29
Set Point of Calcium 9.34 .23 9.79 .25* 9.55 .24
(mg/dl)
CArnax (mg/dl) 8.47 .28 8.14 .25 8.26 .29
CAmin (mg/dl) 10.86 .17 11.03 .28 10.91 .33
Mean SE
*p < 0.05 versus PRE
tP < 0.05 versus PRE and POST
PRE—before calcitriol
POST—after treatment with calcitriol
POST1—after discontinuation of calcitriol
As shown in Table 2 and Figure 1, calcitriol treatment com-
bined with a dialysate calcium of 3.5 mEq/liter (Group 1) resulted
in an increase in the basal calcium from 9.62 0.34 to 10.56
0.31 mg/dl, P < 0.05. Treatment with calcitriol resulted in a
decrease in maximal PTH (P < 0.05) and tended to decrease basal
(P = 0.08 by repeated measures ANOVA) (Fig. 2). Despite this
reduction in PTH, the set point of calcium increased (P < 0.05;
Fig. 1). Discontinuation of calcitriol resulted in a return of the
basal calcium, the set point of calcium, and the basal and maximal
PTH to values similar to baseline.
As shown in Table 3, results in the high calcium dialysate group
(Group II) were similar to those of the calcitriol treatment group
(Group I). An increase in the dialysate calcium concentration and
oral calcium supplementation increased the basal calcium from
9.19 0.31 to 9.84 0.28, P < 0.05 (Fig. 1). A high calcium
dialysate combined with oral calcium supplementation resulted in
a decrease (P < 0.05) in maximal PTH (Fig. 2). Despite the
decrease in maximal PTH, the set point of calcium increased (P <
0.05; Fig. 1). Discontinuation of the high calcium dialysate and
oral calcium supplementation resulted in a return of the basal
Fig. 1. Effect of treatment with calcitriol, treatment with a high calcium
dialysate, or a combination of both groups on the basal (predialysis) serum
calcium (A) and the set point of calcium (B) is shown. Symbols are: (III, pre)
before treatment; (, post) at the end of six weeks of treatment; (i2,
post-i) six weeks after treatment was discontinued; * < 0.05 vs. pre; +P
<0.05 vs. pre and post-i.
calcium, the set point of calcium, and the maximal PTH to
baseline values.
Since the results of the studies on the effect of increasing the
predialysis (basal) serum calcium were similar in both groups, the
groups were combined to increase the power of analysis. After
either calcitriol treatment or an increased calcium dialysate with
oral calcium supplementation, the basal serum calcium increased
from 9.39 0.24 to 10.17 0.24 mg/dI, P < 0.001 (Fig. 1). At the
same time as the serum calcium increased, both basal PTH (P <
0.02) and maximal PTITI (P < 0.005) decreased (Fig. 2). Despite
the reduction in basal and maximal PTH, the set point of calcium
increased (P < 0.001; Fig. 1). The discontinuation of calcitriol and
a high calcium dialysate with oral calcium supplementation re-
sulted in a return of the basal calcium, the set point of calcium,
and the basal and maximal PTH to values not different than
baseline.
Discussion
In the present study in hemodialysis patients with secondary
hyperparathyroidism, treatment with either calcitriol or a high
calcium dialysate increased the predialysis (basal) serum calcium.
Both treatments also resulted in a decrease in PTH levels, but
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Table 4. Biochemical data in the two groups combined.
PRE* POST5 POST1'
PTHmax (pg/mI) 2094 427 1443 395j 2061 529
PTHbase (pg/mi) 893 188 625 193* 920 270
PTHmin (pg/mi) 437 135 378 152 360 113
Basal/Max PTH (%) 43 4 36 6 41 6
Mm/Max PTH (%) 18 3 21 3 16 2
Basal Calcium (mg/dl) 9.39 .24 10.17 .24l 9.57 .22
Set Point of Calcium 9.16 .19 9.57 .18f 9.28 .19
(mgldl)
CAmax (mg/dl) 8.42 .22 8.19 .18 8.14 .18
CAmin (mg/dl) 10.74 .18 10.92 .18 10.80 .23
Mean SE
*p < 0.02 versus PRE and POST
tP < 0.005 versus PRE and POST
PRE—before caicitriol (I) or a high calcium dialysate (II)
POST—after treatment with calcitriol (I) or a high calcium dialysate
(II)
POSTI—after discontinuation of caicitriol (I) or a high calcium
dialysate (II)
Fig. 2. Effect of treatment with calcitriol, treatment with a high calcium
dialysate, or a combination of both groups on the maximal PTH level (A) and
the basal (predialysis) PTH level (B) is shown. Symbols are: (, pre) before
treatment; (, post) at the end of six weeks of treatment; (ui, post-i) six
weeks after treatment was discontinued; *P < 0.05 vs. pre; +P < 0.05 vs.
pre and post-i.
Table 3. Biochemical data in the high calcium diaiysate group.
PRE POST' POST1C
PTHmax (pg/mi) 1642 450 1349 513t 1744 595
PTHbase (pg/mi) 810 266 610 265 908 362
PTHmin (pg/mi) 315 155 279 128 304 136
Basai/MaxPTH(%) 44±6 36±12 45±7
Mm/Max PTH (%) 14 4 18 5 14 3
Basal Calcium (mgldl) 9.19 .31 9.84 .28t 9.26 .26
Set Point of Calcium 9.01 .28 9.39 .22* 9.07 .23
(mgldl)
CAmax (mg/dl) 8.38 .33 8.24 .26 8.05 .21
CAmin (mg/dl) 10.64 .28 10.82 .22 10.71 .32
Mean SE
*p < 0.05 versus PRE
tP < 0.05 versus PRE and POST
a PRE—before a high calcium dialysate
h POST—after treatment with a high calcium dialysate
POST1—after discontinuation of a high calcium dialysate
despite the reduction in PTH, an increase in the Set point of
calcium was observed. Discontinuation of the calcitriol or the high
calcium dialysate resulted in a return of the predialysis serum
calcium, the set point of calcium, and PTH to pretreatment
values. The finding that the set point of calcium increased at the
same time as PTH levels decreased would suggest that the set
point of calcium may not necessarily be an indicator of the
magnitude of hyperparathyroidism and is likely influenced by the
ambient serum calcium concentration.
The meaning of the set point of calcium has been debated since
the term was first popularized by Brown et al more than a decade
ago. In an elegant series of in vitro studies, Brown et al demon-
strated that the set point of calcium was greater in adenomatous
and hyperplastic than normal parathyroid glands [10, 11]. Thus,
the concept evolved that the set point of calcium was an indicator
of the mass of the parathyroid gland. However, it should be
emphasized that the in vitro testing of the PTH-calcium relation-
ship is performed in a closed system that is not influenced by
factors other than the externally manipulated calcium concentra-
tion. In normal humans and animals, the ability of PTH to
modulate serum calcium is affected by calcium absorption from
the gut, calcium deposition and release from bone, and renal
excretion of calcium. Moreover, differences in the potency of PTH
become apparent when normal individuals and hemodialysis
patients are compared; for the same serum calcium concentration,
the PTH level in the hemodialysis patient may be 20 to 40 times
greater [5, 21]. Thus, it is our opinion that in the in vivo setting, the
set point of calcium may best be considered to be an indicator of
the serum calcium concentration at which PTH secretion is
stimulated [5]. In a recent publication, Brown has also arrived at
a similar conclusion for the meaning for the set point of calcium
in in vivo studies [22].
While we believe that the set point of calcium is consistently an
indicator of the serum calcium concentration at which PTH
secretion is stimulated, the set point of calcium may also be in
certain situations an indicator of the magnitude of hyperparathy-
roidism. In individuals with normal renal function, the set point of
calcium is increased in patients with primary hyperparathyroidism
as compared with normal individuals. In this situation, the higher
PTH levels increase the serum calcium by enhancing bone resorp-
tion, augmenting renal calcium reabsorption, and increasing gut
of absorption of calcium through the action of PTH on calcitriol
production [23, 24]. In renal failure because of skeletal resistance
to PTH [13], diminished renal modulation of calcium excretion
[14], and decreased calcitriol levels [15], regulation of serum
calcium is more problematic and less precise than in normal
individuals. This concept is well-illustrated in the recent study by
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Messa et al in which three groups of patients with progressive
renal failure were characterized [251. As expected, PTI-I levels
increased as renal function decreased, but the set point of calcium
for the three groups was similar despite more than a sixfold
difference in PTH levels. Further complicating the situation in
renal failure are the different forms of renal osteodystrophy which
are characterized by low or high bone turnover [26]. In dialysis
patients with a relative PTH deficiency and low bone turnover
such as in adynamic bone or aluminum associated osteomalacia,
the set point of calcium tends to be lower than in dialysis patients
with markedly increased PTH levels and the high-turnover bone
disease, osteitis fibrosa [19]. However, complicating calcium reg-
ulation in the dialysis patient are several confounding variables
which include an inability to modulate serum calcium when
dialysis patients with low bone turnover are challenged with a
calcium load [271, the effect of hyperphosphatemia on calcium
regulation [15], and marked differences in active and quiescent
bone surfaces among patients [281.
Some studies in hemodialysis patients have suggested that since
the calcitriol-induced reduction in PTH levels is accompanied by
a reduction in the set point of calcium, the set point of calcium
reflects a reduction in the magnitude of hyperparathyroidism [3,
7]. However, a reduction in the set point of calcium has not been
observed in all studies in dialysis patients in which calcitriol
treatment redued PTH levels [2, 4, 8, 9] or even in a study in
azotemic patients in which phosphorus restriction reduced PTH
levels [29].
The present study was specifically designed to increase the
serum calcium concentration and decrease PTH levels, and to
evaluate how these changes affected the set point of calcium.
Despite the reduction of PTH levels, the higher predialysis (basal)
calcium resulted in an increase in the set point of calcium.
Calcitriol treatment in the present study was different than in
previous studies in which the goal was to prevent hypercalcemia
and as a result, the dialysate calcium was reduced. Consequently
in those studies, significant increases in the serum calcium were
prevented or were only modest [2—41. The finding that the set
point of calcium can increase at the same time PTH levels are
reduced would appear to adequately demonstrate that the set
point of calcium does not necessarily reflect the magnitude of
hyperparathyroidism.
The set point of calcium increased at the same time as the
predialysis calcium increased and PTH levels decreased. This
result raises the intriguing question whether after a certain length
of time, PTH secretion by the parathyroid gland adapts to the
ambient serum calcium. Previous studies have shown the set point
of calcium to be higher in primary hyperparathyroidism than in
normals [24], and in dialysis patients with marked secondary
hyperparathyroidism than in dialysis patients with lesser degrees
of PTH elevation [19]. These results were at least in part
attributed to the greater secretory capacity and presumed mass of
the parathyroid gland. However, the present situation is different
inasmuch as the set point of calcium increased as the secretory
capacity of the parathyroid gland decreased. While little informa-
tion is available with respect to adaptation of the parathyroid
gland to changes in the serum calcium, studies in normal and
uremic rats and in hemodialysis patients have reported that
calcitonin secretion adapts to the ambient serum calcium [30, 31].
Whether the parathyroid gland has a similar adaptive capacity is
an important question which deserves further study.
In conclusion, the results of the present study in hemodialysis
patients have demonstrated that treatment with either calcitriol or
a high calcium dialysate can increase the set point of calcium
despite a decrease in the PTH level. These results would suggest
that the set point of calcium may not be a reliable indicator of the
magnitude of hyperparathyroidism during calcitriol treatment in
hemodialysis patients. Furthermore, the results of this study
suggest the intriguing possibility that PTH secretion by the
parathyroid gland may adapt to the ambient serum calcium
concentration.
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